Adjunctive immune therapy for fungal infections

A. Casadevall, Liise-anne Pirofski

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Fungal infections in immunocompromised patients can pose difficult problems in clinical management, because the available antifungal chemotherapy is often unable to eradicate the infection in these people. Hence, the use of immune modulating therapy to augment impaired host immune responses - and thus enhance the efficacy of antifungal drugs - is a reasonable approach to improve the prognosis of fungal infections. Advances in biotechnology have produced a variety of biological response modifiers with the potential to serve as adjunctive immune therapy for the treatment of fungal infections, including cytokines, monoclonal antibodies, and cell growth factors. In recent years, immune-modulating therapies have been studied in an effort to define their potential use for the treatment of fungal infections. Much of the available information on the use of this approach is encouraging and invites further investigation - with the caveats that the information is mostly anecdotal and that immune-modulating therapy occasionally has produced adverse effects.

Original languageEnglish (US)
Pages (from-to)1048-1056
Number of pages9
JournalClinical Infectious Diseases
Volume33
Issue number7
DOIs
StatePublished - Oct 1 2001

Fingerprint

Mycoses
Therapeutics
Immunologic Factors
Immunocompromised Host
Biotechnology
Intercellular Signaling Peptides and Proteins
Monoclonal Antibodies
Cytokines
Drug Therapy
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Adjunctive immune therapy for fungal infections. / Casadevall, A.; Pirofski, Liise-anne.

In: Clinical Infectious Diseases, Vol. 33, No. 7, 01.10.2001, p. 1048-1056.

Research output: Contribution to journalArticle

@article{7b9f57442cdb4e2183bc1b1098cbfd88,
title = "Adjunctive immune therapy for fungal infections",
abstract = "Fungal infections in immunocompromised patients can pose difficult problems in clinical management, because the available antifungal chemotherapy is often unable to eradicate the infection in these people. Hence, the use of immune modulating therapy to augment impaired host immune responses - and thus enhance the efficacy of antifungal drugs - is a reasonable approach to improve the prognosis of fungal infections. Advances in biotechnology have produced a variety of biological response modifiers with the potential to serve as adjunctive immune therapy for the treatment of fungal infections, including cytokines, monoclonal antibodies, and cell growth factors. In recent years, immune-modulating therapies have been studied in an effort to define their potential use for the treatment of fungal infections. Much of the available information on the use of this approach is encouraging and invites further investigation - with the caveats that the information is mostly anecdotal and that immune-modulating therapy occasionally has produced adverse effects.",
author = "A. Casadevall and Liise-anne Pirofski",
year = "2001",
month = "10",
day = "1",
doi = "10.1086/322710",
language = "English (US)",
volume = "33",
pages = "1048--1056",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Adjunctive immune therapy for fungal infections

AU - Casadevall, A.

AU - Pirofski, Liise-anne

PY - 2001/10/1

Y1 - 2001/10/1

N2 - Fungal infections in immunocompromised patients can pose difficult problems in clinical management, because the available antifungal chemotherapy is often unable to eradicate the infection in these people. Hence, the use of immune modulating therapy to augment impaired host immune responses - and thus enhance the efficacy of antifungal drugs - is a reasonable approach to improve the prognosis of fungal infections. Advances in biotechnology have produced a variety of biological response modifiers with the potential to serve as adjunctive immune therapy for the treatment of fungal infections, including cytokines, monoclonal antibodies, and cell growth factors. In recent years, immune-modulating therapies have been studied in an effort to define their potential use for the treatment of fungal infections. Much of the available information on the use of this approach is encouraging and invites further investigation - with the caveats that the information is mostly anecdotal and that immune-modulating therapy occasionally has produced adverse effects.

AB - Fungal infections in immunocompromised patients can pose difficult problems in clinical management, because the available antifungal chemotherapy is often unable to eradicate the infection in these people. Hence, the use of immune modulating therapy to augment impaired host immune responses - and thus enhance the efficacy of antifungal drugs - is a reasonable approach to improve the prognosis of fungal infections. Advances in biotechnology have produced a variety of biological response modifiers with the potential to serve as adjunctive immune therapy for the treatment of fungal infections, including cytokines, monoclonal antibodies, and cell growth factors. In recent years, immune-modulating therapies have been studied in an effort to define their potential use for the treatment of fungal infections. Much of the available information on the use of this approach is encouraging and invites further investigation - with the caveats that the information is mostly anecdotal and that immune-modulating therapy occasionally has produced adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=0035478082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035478082&partnerID=8YFLogxK

U2 - 10.1086/322710

DO - 10.1086/322710

M3 - Article

C2 - 11528579

AN - SCOPUS:0035478082

VL - 33

SP - 1048

EP - 1056

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -